FDA
-
-
-
-
-
-
-
ASCO 2026: Bayer to Present New Data Across Oncology Portfolio
-
-
-
-
-
-
-
Investigational PET Tracer Iodine 124 Evuzamitide from Bayer Met Primary Endpoints in Phase III Study in Patients Suspected to Have Cardiac Amyloidosis
-
-
-
-
-
-
-
Bayer’s Asundexian Demonstrated a Substantial 26% Reduction in Stroke After a Non-Cardioembolic Ischemic Stroke or High-Risk Transient Ischemic Attack, With No Increase in ISTH Major Bleeding Versus
-
-
-
-
-
-
-
Bayer’s MEDRAD® Centargo Multi-Patient CT Injection System Now With A Wider Range of Compatible CT Contrast Agents and Presentations
-
-
-
-
-
-
-
One A Day® Unveils Bold New Brand Identity and Platform: “The ONE for you”
-
-
-
-
326,106 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

